Evaluation of rapid tests for diagnosis of acute hepatitis E

• Rapid tests for anti-HEV IgM were compared with ELISA and Real-Time PCR assays.
• Data suggest the potential use of anti-HEV IgM Rapid assays as a first line test.
• Rapid tests can be useful for patients with chronic liver disease or pregnant women.

BackgroundHepatitis E virus diagnosis still presents difficulties due to discordant results among diagnostic tests.ObjectivesThe aim of this study was to evaluate the performance of two rapid tests for detection of anti-HEV IgM antibodies.Study designThe rapid tests were compared with three commercial anti-HEV ELISA assays and one Real-Time PCR assay on 59 sera from patients with acute viral non-AC hepatitis.ResultsThe presence of anti-HEV IgM antibodies was evaluated by two rapid tests (Wantai and Assure) on 25 HEV RNA positive samples. Anti-HEV IgM antibodies were detected in 24/25 and 23/25 samples respectively. The sensitivity and specificity of Wantai and Assure Rapid tests were evaluated using the 25 HEV RNA positive samples and 50 HEV RNA negative samples (including sera from acute-phase HAV and HBV infections and blood donors). Overall, the sensitivity of Wantai Rapid and Assure Rapid tests was 96.1% and 92.6% respectively; the specificity of the 2 tests was 100%.ConclusionOur data suggest the potential use of anti-HEV IgM rapid assays as a first line test in primary health care settings, particularly useful for patients with chronic liver disease or pregnant women who urgently need an antiviral treatment.